newsfilter
← Latest News
GlobeNewswire·

Harrow Announces Third Quarter 2026 Financial Results

HROW
  • Harrow reported record third-quarter 2026 revenue of $99.3 million, representing a 41% sequential increase and a 39% year-over-year rise.
  • Branded products generated $83.5 million in revenue, accounting for approximately 84% of the total, with a 62% year-over-year growth rate.
  • GAAP net income for the quarter was $9.8 million, which included a $5.0 million litigation settlement gain, compared to a net loss of $17.3 million in the previous quarter.
  • Adjusted EBITDA reached $21.2 million, a significant improvement from a $1.2 million loss in the prior quarter, though it remained below the $22.8 million recorded in the third quarter of 2025.
  • The company reaffirmed full-year 2026 revenue guidance of $350 million to $365 million but updated its Adjusted EBITDA outlook to more than $40 million for the year, including a fourth-quarter projection of over $33 million.
  • Cash and cash equivalents totaled $75.3 million as of September 30, 2026.
  • VEVYE achieved record quarterly revenue of $39.7 million with a 75% year-over-year increase, while total prescriptions rose 83% year over year.
  • IHEEZO revenue grew to $25.3 million with unit demand increasing 21% year over year, despite a slight sequential decline due to seasonality.
  • TRIESENCE posted record revenue of $10.7 million under Harrow ownership, with unit demand surging 110% year over year.
  • BYOOVIZ completed its first full quarter of commercialization with strengthening demand momentum entering the fourth quarter.
  • Harrow acquired TYRVAYA on October 1, 2026, adding a complementary dry eye treatment to its portfolio with initial revenue expected in the fourth quarter.
  • The company restructured its commercial organization into four focused teams: Ocular Surface Disease, Retina, Surgical, and Access+.
  • HarrowRx launched on November 1, 2026, as an integrated digital platform for prescribing all Harrow products.
  • The Phase 4 QUELL study for IHEEZO did not meet its primary non-inferiority endpoint but showed favorable secondary results regarding patient comfort and tolerability.
  • Harrow expects to submit its NDA for G-MELT before the end of 2026 following a pre-NDA meeting with the FDA.
  • The company anticipates launching at least one new product annually through the end of the decade, starting with the 2027 U.S. launch of OPUVIZ.
  • Conference calls to discuss these results were scheduled for November 10, 2026, with a webcast available on the company's investor website.
Company
Harrow, Inc.
Keywords
Nasdaq:HROW, Harrow, Inc.